Does long-term postoperative adjuvant chemotherapy of UFT/LV improve survival in a primary tumor resection-pulmonary metastasis model?
Long-term administration of UFT/LV as postoperative adjuvant chemotherapy may be potentially beneficial.
Our results suggest that low endogenous SPARC expression is a constant feature of BCR/ABL positive cells and that IM treatment induces SPARC overproduction by normal cells. This exogenous SPARC may inhibit CML cell proliferation and may synergize with IM activity against CML.